Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Centre Oscar Lambret
Children's Oncology Group
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
St. Jude Children's Research Hospital
Cue Biopharma
Baylor College of Medicine
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Nationwide Children's Hospital
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
University Hospital, Antwerp
Children's Hospital of Philadelphia
City of Hope Medical Center
Birmingham Women's and Children's NHS Foundation Trust
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Sellas Life Sciences Group
University of Virginia
Bayer
Sumitomo Pharma America, Inc.
National Cancer Institute (NCI)
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
New York Medical College